A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice.

ABSTRACT:

Introduction

Fruquintinib is approved in China for patients with metastatic colorectal cancer (CRC) who progressed after 2 lines of chemotherapy. This postmarketing study was conducted to evaluate the safety of fruquintinib in the Chinese population, including previously treated patients with advanced CRC and other solid tumors.

Methods

Patients in the first cycle of fruquintinib or expected to start fruquintinib within a week were enrolled. Fruquintinib was administrated according to the label or per physicians' discretion. Patient characteristics and safety information were collected at baseline, 1 month, and 6 months after consent (or 30 days after the last dose).

Results

Overall, 3005 patients enrolled between April 24, 2019 and September 27, 2022. All enrolled pa

SUBMITTER: Li J 

PROVIDER: S-EPMC11299944 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature